[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
    "summary": "Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 1.3% and the S",
    "url": "https://finnhub.io/api/news?id=b7735e7988c593e5855b404c5dbaaa4b69f1182b7a4a8898c50b1507c5ace208",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772226149,
      "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
      "id": 139257032,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 1.3% and the S",
      "url": "https://finnhub.io/api/news?id=b7735e7988c593e5855b404c5dbaaa4b69f1182b7a4a8898c50b1507c5ace208"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Higher Friday Afternoon",
    "summary": "Health care stocks rose Friday afternoon, with the NYSE Health Care Index and the State Street Healt",
    "url": "https://finnhub.io/api/news?id=26499900e1001f4237930815b649ff63f8fc563f2b951ed39ab682bd1801eb33",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772218889,
      "headline": "Sector Update: Health Care Stocks Higher Friday Afternoon",
      "id": 139255600,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks rose Friday afternoon, with the NYSE Health Care Index and the State Street Healt",
      "url": "https://finnhub.io/api/news?id=26499900e1001f4237930815b649ff63f8fc563f2b951ed39ab682bd1801eb33"
    }
  },
  {
    "ts": null,
    "headline": "IHE: U.S. Pharmaceuticals ETF With Excellent GARP Features",
    "summary": "IHE: U.S. Pharmaceuticals ETF With Excellent GARP Features",
    "url": "https://finnhub.io/api/news?id=fd445e2724625e6a109ff734f0648892f87df7df2e8e983c77c57a0bb579559e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772209080,
      "headline": "IHE: U.S. Pharmaceuticals ETF With Excellent GARP Features",
      "id": 139256613,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=fd445e2724625e6a109ff734f0648892f87df7df2e8e983c77c57a0bb579559e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Vs. Novo Nordisk: The Valuation Gap Is Unreasonable",
    "summary": "Eli Lilly Vs. Novo Nordisk: The Valuation Gap Is Unreasonable",
    "url": "https://finnhub.io/api/news?id=ff784ee478ec12b518ba9684dde693c479d016f48cb5fa3c7a4456ab114810e5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772205234,
      "headline": "Eli Lilly Vs. Novo Nordisk: The Valuation Gap Is Unreasonable",
      "id": 139256030,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=ff784ee478ec12b518ba9684dde693c479d016f48cb5fa3c7a4456ab114810e5"
    }
  },
  {
    "ts": null,
    "headline": "5 US Blue Chip Giants That Have Paid Dividends for Over 100 Years",
    "summary": "Investors love dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid total return. Total return includes interest, capital gains, dividends, and distributions realized over time. In other words, the total return on an investment or portfolio consists of income and stock appreciation. At 24/7 Wall St., we have focused ... 5 US Blue Chip Giants That Have Paid Dividends for Over 100 Years",
    "url": "https://finnhub.io/api/news?id=b507cdaa91f37bb7cdb862fa0c32675e4f43a20a2c928c0fa2fbabc532723a6f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772197868,
      "headline": "5 US Blue Chip Giants That Have Paid Dividends for Over 100 Years",
      "id": 139249979,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investors love dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid total return. Total return includes interest, capital gains, dividends, and distributions realized over time. In other words, the total return on an investment or portfolio consists of income and stock appreciation. At 24/7 Wall St., we have focused ... 5 US Blue Chip Giants That Have Paid Dividends for Over 100 Years",
      "url": "https://finnhub.io/api/news?id=b507cdaa91f37bb7cdb862fa0c32675e4f43a20a2c928c0fa2fbabc532723a6f"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata",
    "summary": "Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Olumiant (baricitinib) for the treatment of adolescents (ages 12 to <18) with severe alopecia areata (AA). AA is a chronic immune disease that can have an especially devastating social and emotional impact on young patients and their families, as early onset AA can be more severe and lead to",
    "url": "https://finnhub.io/api/news?id=5a22d64cea56d449882ee250a1f5ef3684c008211251611b7e216675ce0926d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772197860,
      "headline": "Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata",
      "id": 139247174,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Olumiant (baricitinib) for the treatment of adolescents (ages 12 to <18) with severe alopecia areata (AA). AA is a chronic immune disease that can have an especially devastating social and emotional impact on young patients and their families, as early onset AA can be more severe and lead to",
      "url": "https://finnhub.io/api/news?id=5a22d64cea56d449882ee250a1f5ef3684c008211251611b7e216675ce0926d4"
    }
  },
  {
    "ts": null,
    "headline": "IUSG: Growth ETF With Average Results",
    "summary": "The iShares Core S&P US Growth ETF offers concentrated S&P 900 growth exposure, with 47% in technology. Click here to learn more about IUSG.",
    "url": "https://finnhub.io/api/news?id=a810a219152a85ee2e71ac78c3342a19d816b338afd36cc4953b7e114de27802",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772190117,
      "headline": "IUSG: Growth ETF With Average Results",
      "id": 139250288,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/926482498/image_926482498.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The iShares Core S&P US Growth ETF offers concentrated S&P 900 growth exposure, with 47% in technology. Click here to learn more about IUSG.",
      "url": "https://finnhub.io/api/news?id=a810a219152a85ee2e71ac78c3342a19d816b338afd36cc4953b7e114de27802"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly And Incyte Say EMA's CHMP Issues Positive Opinion For Olumiant For Treatment Of Adolescents With Severe Alopecia Areata",
    "summary": "The positive opinion is based on data from the Phase 3 BRAVE-AA-PEDS study, in which 42% of patients with severe alopecia areata (AA) reached 80% or more scalp hair coverage at 36 weeksThe study is the first",
    "url": "https://finnhub.io/api/news?id=17d1d9d5e62292cccaf9a4a0b469578da98e2c16e1bf6d7bdcd591afb3ce098d",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772183633,
      "headline": "Eli Lilly And Incyte Say EMA's CHMP Issues Positive Opinion For Olumiant For Treatment Of Adolescents With Severe Alopecia Areata",
      "id": 139246613,
      "image": "",
      "related": "LLY",
      "source": "Benzinga",
      "summary": "The positive opinion is based on data from the Phase 3 BRAVE-AA-PEDS study, in which 42% of patients with severe alopecia areata (AA) reached 80% or more scalp hair coverage at 36 weeksThe study is the first",
      "url": "https://finnhub.io/api/news?id=17d1d9d5e62292cccaf9a4a0b469578da98e2c16e1bf6d7bdcd591afb3ce098d"
    }
  },
  {
    "ts": null,
    "headline": "RBC Capital Initiates Eli Lilly (LLY), Cites Long-Term Leadership in Obesity Market",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 14 Best GARP Stocks to Buy According to Analysts. On February 25, RBC Capital initiated coverage of Eli Lilly and Company (NYSE:LLY) with an Outperform rating and a $1,250 price target. The firm said Lilly’s obesity franchise is positioned to dominate the market through 2030. The […]",
    "url": "https://finnhub.io/api/news?id=8e026e8cac360ea04c3128325fcbce3ac80d988a7d3e1e669486e9caca9b5fc1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772173098,
      "headline": "RBC Capital Initiates Eli Lilly (LLY), Cites Long-Term Leadership in Obesity Market",
      "id": 139244653,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 14 Best GARP Stocks to Buy According to Analysts. On February 25, RBC Capital initiated coverage of Eli Lilly and Company (NYSE:LLY) with an Outperform rating and a $1,250 price target. The firm said Lilly’s obesity franchise is positioned to dominate the market through 2030. The […]",
      "url": "https://finnhub.io/api/news?id=8e026e8cac360ea04c3128325fcbce3ac80d988a7d3e1e669486e9caca9b5fc1"
    }
  }
]